Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/39514
Registro completo de metadados
Campo DCValorIdioma
dc.creatorMartinez, Miguel Angel-
dc.date.accessioned2020-03-27T19:48:31Z-
dc.date.available2020-03-27T19:48:31Z-
dc.date.issued2020-
dc.identifier.citationMARTINEZ, M. A. Compounds with therapeutic potential against Novel Respiratory 2019 Coronavirus. Antimicrobial Agents Chemother, [S.l.], 2020.pt_BR
dc.identifier.urihttps://aac.asm.org/content/early/2020/03/03/AAC.00399-20pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/39514-
dc.description.abstractCurrently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb against MERS-CoV in a transgenic humanized mice model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, has suggested that pro-inflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections.pt_BR
dc.languageen_USpt_BR
dc.publisherAmerican Society for Microbiologypt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceAntimicrobial Agents Chemotherpt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus (SARS-CoV)pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectMiddle East respiratory syndrome corona virus (MERS-CoV)pt_BR
dc.subjectCOVID-19pt_BR
dc.subjectRemdesivirpt_BR
dc.titleCompounds with therapeutic potential against Novel Respiratory 2019 Coronaviruspt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.